JNJ | Johnson & Johnson | $0.6t | $276.98 | -1.8% | 4.4M |
ABBV | ABBVIE INC. | $0.5t | $291.04 | -1.0% | 2.4M |
AMGN | Amgen Inc | $249.4b | $455.45 | -1.0% | 1.2M |
BMY | Bristol-Myers Squibb Co. | $126.1b | $61.06 | -3.3% | 12.0M |
REGN | Regeneron Pharmaceuticals Inc | $100.7b | $955.00 | +0.6% | 503.8K |
ROIV | Roivant Sciences Ltd. Common Shares | $26.0b | $37.60 | +0.3% | 5.0M |
APGE | Apogee Therapeutics, Inc. Common Stock | $10.2b | $135.09 | 0.0% | N/A |
TGTX | TG Therapeutics, Inc. | $9.3b | $62.69 | -0.1% | 1.5M |
SYRE | Spyre Therapeutics, Inc. Common Stock | $9.3b | $93.89 | -5.6% | 932.8K |
PTGX | Protagonist Therapeutics, Inc | $9.1b | $128.01 | -0.1% | 340.9K |
IBRX | ImmunityBio, Inc. Common Stock | $8.8b | $6.28 | +4.7% | 10.3M |
ORKA | Oruka Therapeutics, Inc. Common Stock | $6.6b | $96.38 | -2.8% | 651.8K |
IMVT | Immunovant, Inc. Common Stock | $6.0b | $33.23 | -0.2% | 730.6K |
APLS | Apellis Pharmaceuticals, Inc. Common Stock | $5.2b | $41.04 | +0.0% | 68.6M |
DNTH | Dianthus Therapeutics, Inc. Common Stock | $4.6b | $87.34 | -2.9% | 449.7K |
ARQT | Arcutis Biotherapeutics, Inc. Common Stock | $4.0b | $27.33 | +0.7% | 1.1M |
ADMA | ADMA Biologics, Inc. | $2.5b | $13.71 | +1.2% | 2.4M |
RCUS | Arcus Biosciences, Inc. | $2.4b | $15.97 | -2.8% | 1.7M |
BHVN | Biohaven Ltd. | $2.4b | $13.11 | -4.1% | 1.3M |
CLDX | Celldex Therapeutics, Inc | $2.3b | $28.02 | -1.9% | 403.6K |
XNCR | Xencor, Inc. | $2.3b | $34.49 | -2.5% | 764.6K |
AUPH | Aurinia Pharmaceuticals Inc | $2.2b | $15.53 | -0.5% | 640.1K |
VERA | Vera Therapeutics, Inc. Class A Common Stock | $2.2b | $26.68 | -2.7% | 1.0M |
SEPN | Septerna, Inc. Common Stock | $2.0b | $39.74 | -3.9% | 218.8K |
TRAX | First Tracks Biotherapeutics, Inc. Ordinary Shares | $1.9b | $43.57 | -6.5% | 513.2K |
ZBIO | Zenas BioPharma, Inc. Common Stock | $1.8b | $26.45 | -0.6% | 365.9K |
FBRX | Forte Biosciences, Inc. Common Stock | $1.6b | $76.98 | 0.0% | N/A |
ANAB | AnaptysBio, Inc. Common Stock | $1.5b | $46.45 | -0.3% | 532.3K |
NKTR | Nektar Therapeutics | $1.3b | $36.67 | -1.4% | 569.1K |
CGEM | Cullinan Therapeutics, Inc. Common Stock | $1.0b | $9.28 | -2.4% | 1.5M |
MLTX | MoonLake Immunotherapeutics Class A Ordinary Shares | $1.0b | $11.46 | -3.9% | 1.1M |
JBIO | Jade Biosciences, Inc. Common Stock | $0.9b | $15.44 | +0.7% | 1.9M |
ODTX | Odyssey Therapeutics, Inc. Common Stock | $0.9b | $19.40 | +0.1% | 256.9K |
RIGL | Rigel Pharmaceuticals Inc. (New) | $0.9b | $42.39 | -1.6% | 195.1K |
ALMS | Alumis Inc. Common Stock | $0.8b | $4.88 | -5.6% | 1.6M |
CRVS | Corvus Pharmaceuticals, Inc. | $0.8b | $10.33 | -4.1% | 793.3K |
ANNX | Annexon, Inc. Common Stock | $0.8b | $3.47 | -2.5% | 2.5M |
IMMX | Immix Biopharma, Inc. Common Stock | $0.6b | $7.72 | -3.3% | 764.8K |
ACRS | Aclaris Therapeutics, Inc. | $0.6b | $3.37 | -6.0% | 2.9M |
CLYM | Climb Bio, Inc. Common Stock | $0.6b | $9.79 | -1.5% | 486.2K |
STTK | Shattuck Labs, Inc. Common Stock | $0.5b | $4.49 | -1.3% | 643.1K |
AVTX | Avalo Therapeutics, Inc. Common Stock | $388.8m | $7.13 | -3.1% | 2.9M |
ZURA | Zura Bio Limited Class A Ordinary Shares | $322.0m | $1.03 | -4.2% | 3.4M |
KYTX | Kyverna Therapeutics, Inc. Common Stock | $319.1m | $4.79 | -1.1% | 513.6K |
ENTA | Enanta Pharmaceuticals, Inc | $302.0m | $8.88 | -18.4% | 795.8K |
SABS | SAB Biotherapeutics, Inc. Common Stock | $283.9m | $2.94 | -1.3% | 275.4K |
IPSC | Century Therapeutics, Inc. Common Stock | $275.2m | $1.38 | -16.5% | 619.0K |
QTTB | Q32 Bio Inc. Common Stock | $260.8m | $8.37 | +4.2% | 593.4K |
FATE | Fate Therapeutics, Inc. | $244.4m | $1.06 | -11.0% | 2.3M |
CABA | Cabaletta Bio, Inc. Common Stock | $240.8m | $1.03 | -8.6% | 5.1M |